PPIDT00447
Drug Information
| Name | Satralizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15762 |
| Type | biotech |
| Indication | Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.[L15536] In Canada, it is also used in adolescent patients for the same indication.[L15546] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
120 mg/ml
|
| Injection, solution | Subcutaneous |
120 mg/1mL
|
| Injection, solution | Subcutaneous |
120 MG
|
| Solution | Subcutaneous |
120 mg / mL
|
| Solution | Subcutaneous |
120 mg/1ml
|
| Injection, solution | Subcutaneous |
120 mg/ml
|
| Solution | Subcutaneous |
12000000 mg
|